title: Delta-9-tetrahydrocannabinol differently affects striatal c-Fos expression following haloperidol or clozapine administration.
abstract: It was previously shown that haloperidol, but not clozapine, induced intense rat catalepsy when co-administered with delta-9-tetrahydrocannabinol. The present study investigated whether similar alterations could be observed on striatal c-Fos immunoreactivity after administration of the same drug combinations. Western Blot and immunocytochemistry stereological analyses indicated that delta-9-tetrahydrocannabinol (0.5 mg/kg) increased striatal c-Fos immunoreactivity induced by haloperidol (0.1 mg/kg). Conversely, no significant alterations of striatal c-Fos immunoreactivity were observed after injections of clozapine (10 mg/kg)+vehicle, clozapine+delta-9-tetrahydrocannabinol or vehicle+delta-9-tetrahydrocannabinol. The present results indicate that the behavioral effects induced by delta-9-tetrahydrocannabinol in haloperidol- and clozapine-treated rats are associated with different striatal c-Fos expressions.
authors.affiliation: C.N.R., Institute of Biomedical Technology, Sect. Cagliari, Technological Park of Sardinia "Sardegna Ricerche", Pula, Cagliari, Italy. giorgio.marchese@itb.cnr.it
authors.forename: Giorgio
authors.initials: G
authors.lastname: Marchese
authors.forename: Angela
authors.initials: A
authors.lastname: Sanna
authors.forename: Gianluca
authors.initials: G
authors.lastname: Casu
authors.forename: Paola
authors.initials: P
authors.lastname: Casti
authors.forename: Gabriele Pinna
authors.initials: GP
authors.lastname: Spada
authors.forename: Stefania
authors.initials: S
authors.lastname: Ruiu
authors.forename: Luca
authors.initials: L
authors.lastname: Pani
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D015153:Blotting, Western; D003024:Clozapine / Q000494:pharmacology*; D013759:Dronabinol / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D015870:Gene Expression / Q000187:drug effects; D016762:Genes, fos / Q000187:drug effects*; D006220:Haloperidol / Q000494:pharmacology*; D007150:Immunohistochemistry; D008297:Male; D017072:Neostriatum / Q000187:drug effects / Q000378:metabolism*; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D010880:Piperidines / Q000494:pharmacology; D011619:Psychotropic Drugs / Q000494:pharmacology*; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D043884:Receptor, Cannabinoid, CB1 / Q000187:drug effects; D000077285:Rimonabant
chemical_list: D014150:Antipsychotic Agents; D010880:Piperidines; D011619:Psychotropic Drugs; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D013759:Dronabinol; D003024:Clozapine; D006220:Haloperidol; D000077285:Rimonabant